Bulletin
Investor Alert

New York Markets Close in:

Europe Markets Archives | Email alerts

March 16, 2021, 11:54 a.m. EDT

European stocks move higher despite anxieties around rollout of COVID-19 vaccines

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    STOXX Europe 600 Index (SXXP)
  • X
    FTSE 100 Index (UKX)
  • X
    CAC 40 Index (PX1)

or Cancel Already have a watchlist? Log In

Jack Denton

European stocks opened higher on Tuesday, chasing Monday’s momentum from Wall Street as concerns continue over the rollout of COVID-19 vaccines across the continent.

The pan-European Stoxx 600 /zigman2/quotes/210599654/delayed XX:SXXP +0.07% rose near 0.9%, while London’s FTSE 100 /zigman2/quotes/210598409/delayed UK:UKX +0.25% was 0.7% higher. The CAC 40 /zigman2/quotes/210597958/delayed FR:PX1 -0.31% in Paris was up 0.4% and Frankfurt’s DAX /zigman2/quotes/210597999/delayed DX:DAX +0.36% lifted 0.9%.

The Dow was more than 120 points lower in midday trading, after the index hit a new high on Monday and closed at 32,953.

Broad worries about the rollout of COVID-19 vaccines in Europe persisted into Tuesday, after contributing to driving down European stocks on Monday as the Dow /zigman2/quotes/210598065/realtime DJIA +0.15% and S&P 500 /zigman2/quotes/210599714/realtime SPX +0.46% indexes posted a third day of record highs on Wall Street.

“It seems likely that last night’s late U.S. rebound is likely to aid into a modestly positive start for markets here in Europe later,” said Michael Hewson, an analyst at CMC Markets.

“One positive sign among all the jitters is that the EuroStoxx600 Travel and Leisure index has recovered all of its post pandemic losses, posting a record high yesterday, although the airline stocks have lagged behind those of the better performers in that particular sector, which have been the gaming companies,” Hewson added.

The latest inoculation worries center on the vaccine developed by AstraZeneca and Oxford University. Germany, France, Italy, Spain, and the Netherlands joined countries across Europe on Monday, pausing the use of the vaccine following concerns that it could contribute to blood clots.

The World Health Organization and the European Medicines Agency maintain that the vaccine is safe. It continues to be used in the U.K., where it has been distributed to more than 10 million people with no evidence of related serious adverse events, according to the WHO.

Also read: Germany and France become latest countries to halt use of AstraZeneca COVID-19 vaccine over blood clot concerns

“The problems are also likely to delay the timeline of an economic reopening across Europe, as the vaccination program sees vaccine shortages get more acute, with the result that more people are likely to become infected, and possibly die,” Hewson said.

Shares in German auto giant Volkswagen /zigman2/quotes/206919008/delayed XE:VOW +2.01% buoyed Frankfurt trading, rising around 7.5% following the release of the company’s annual report for 2020. The group continued to press its ambitious plan to pivot toward electric vehicles, and said that targeted cost cuts would boost margins in the next few years.

Shares in Varta /zigman2/quotes/207924135/delayed XE:VAR1 +0.24% , a German manufacturer of batteries, jumped 16%.

Credit Suisse /zigman2/quotes/205269278/delayed CH:CSGN +1.41% stock rose more than 2% in early trading before giving up gains, after as the Swiss bank issued a trading update noting a very strong start to 2021, including the highest level of pre-tax income in January and February in more than 10 years.

Shares in NatWest /zigman2/quotes/209265718/delayed UK:NWG +0.74% fell near 3% after the British financial regulator, the Financial Conduct Authority (FCA) brought money laundering charges against the bank. The FCA alleges that NatWest failed to comply with anti-money-laundering rules.

Morphosys /zigman2/quotes/205694191/delayed XE:MOR +0.88% stock was one of the biggest fallers in Europe, with shares down more than 10%. Full year earnings released today failed to impress investors in the biopharmaceutical company, dual-listed in Frankfurt and on the Nasdaq.

/zigman2/quotes/210599654/delayed
XX : STOXX
472.21
+0.33 +0.07%
Volume: 0.00
Oct. 25, 2021 5:50p
loading...
/zigman2/quotes/210598409/delayed
UK : FTSE UK
7,222.82
+18.27 +0.25%
Volume: 496,731
Oct. 25, 2021 4:58p
loading...
/zigman2/quotes/210597958/delayed
FR : France: Euronext Paris
6,712.87
-20.82 -0.31%
Volume: 58,586
Oct. 25, 2021 6:05p
loading...
/zigman2/quotes/210597999/delayed
DAX
DX : Xetra Indices
15,599.23
+56.25 +0.36%
Volume: 51,296
Oct. 25, 2021 6:30p
loading...
/zigman2/quotes/210598065/realtime
US : Dow Jones Global
35,731.62
+54.60 +0.15%
Volume: 204.03M
Oct. 25, 2021 3:46p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,565.99
+21.09 +0.46%
Volume: 1.38B
Oct. 25, 2021 3:46p
loading...
/zigman2/quotes/206919008/delayed
XE : Germany: Xetra
283.80
+5.60 +2.01%
Volume: 54,943
Oct. 25, 2021 6:30p
P/E Ratio
8.07
Dividend Yield
1.69%
Market Cap
€122.53 billion
Rev. per Employee
€336,391
loading...
/zigman2/quotes/207924135/delayed
XE : Germany: Xetra
127.40
+0.30 +0.24%
Volume: 95,151
Oct. 25, 2021 6:30p
P/E Ratio
50.92
Dividend Yield
1.95%
Market Cap
€5.14 billion
Rev. per Employee
€189,700
loading...
/zigman2/quotes/205269278/delayed
CH : Switzerland: SWX
CHF 9.77
+0.14 +1.41%
Volume: 4.84M
Oct. 25, 2021 5:30p
P/E Ratio
142.57
Dividend Yield
1.02%
Market Cap
CHF23.22 billion
Rev. per Employee
CHF621,202
loading...
/zigman2/quotes/209265718/delayed
UK : U.K.: London
£ 232.00
+1.70 +0.74%
Volume: 10.63M
Oct. 25, 2021 4:35p
P/E Ratio
15.36
Dividend Yield
0.03%
Market Cap
£26.23 billion
Rev. per Employee
£237,730
loading...
/zigman2/quotes/205694191/delayed
XE : Germany: Xetra
39.04
+0.34 +0.88%
Volume: 187,109
Oct. 25, 2021 6:30p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
€1.32 billion
Rev. per Employee
€532,843
loading...

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.